

and Rules of Evidence, Judicial Conference of the United States.

**ACTION:** Notice of cancellation of two open hearings and rescheduling of one open hearing.

**SUMMARY:** The following public hearings on proposed rules amendments have been canceled:

- Bankruptcy Rules in Washington, DC., on January 24, 2003; and
- Criminal Rules in Atlanta, Georgia, on January 31, 2003.

The public hearing on proposed amendments to the Evidence Rules, originally scheduled for January 27, 2003, has been rescheduled for April 25, 2003, in Washington, DC. Original notice of hearings appeared in the **Federal Register** of August 23, 2002.

#### Notice of Open Hearings

**FOR FURTHER INFORMATION CONTACT:** John K. Rabiej, Chief, Rules Committee Support Office, Administrative Office of the United States Courts, One Columbus Circle, NE., Washington, DC 20544, telephone (202) 502-1820.

Dated: January 9, 2003.

**John K. Rabiej,**

*Chief, Rules Committee Support Office.*

[FR Doc. 03-835 Filed 1-14-03; 8:45 am]

**BILLING CODE 2210-55-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances; Notice of Registration

By Notice dated July 29, 2002, and published in the **Federal Register** on August 19, 2002, (67 FR 53810), Abbott Laboratories, 1776 North Centennial Drive, McPherson, Kansas 67460-1247, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of remifentanyl (9739), a basic class of controlled substance listed in Schedule II.

The firm plans to import the remifentanyl to manufacture Ultiva for the U.S. market.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Abbott Laboratories to import remifentanyl is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Abbott Laboratories on a regular basis to ensure that the company's continued registration is

consistent with the public interest. This investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal regulations, section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: December 13, 2002.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-769 Filed 1-14-03; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances Notice of Registration

By Notice dated June 10, 2002, and published in the **Federal Register** on June 20, 2002, (67 FR 42059), Celltech Manufacturing CA, Inc., 3501 West Garry Avenue, Santa Ana, California 92704, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture the listed controlled substance to make finished dosage forms for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Celltech Manufacturing CA, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Celltech Manufacturing CA, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security system, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that

the application submitted by the above firm for registration as a bulk manufacture of the basic class of controlled substance listed above is granted.

Dated: December 13, 2002.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-768 Filed 1-14-03; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated June 7, 2002, and published in the **Federal Register** on June 20, 2002, (67 FR 42059), National Center for Development of Natural Products, The University of Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38677, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the controlled substances listed below:

Drug	Schedule
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I

The firm plans to bulk manufacture for product development.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of National Center for Development of Natural Products to manufacture the listed controlled substances is consistent with the public interest at this time. This determination was based on, among other things, DEA's on-site investigation of the National Center for Development for Natural Products. The investigation included inspection and testing of the applicant's qualifications and experience, verification of the applicant's compliance with state and local laws, and a review of the firm's background and history. DEA has further determined that the registration will be consistent with United States obligations under international treaties. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of